Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Botanical Solution (BSI) is a biotechnology company that leverages its proprietary Advanced Botanical-Gold (ABG) platform to produce high-value plant-derived compounds through sustainable tissue culture methods. The company's primary focus is the production of QS-21, a gold-standard vaccine adjuvant traditionally sourced from the bark of the Chilean Soapbark tree, which BSI produces in a lab-controlled environment to ensure scalability and purity. BSI also markets Quillibrium, a successful biofungicide used in high-value crops, through a global partnership with Syngenta. By overcoming the supply chain limitations of rare botanical materials, BSI supports the development of next-generation vaccines and sustainable agricultural solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Botanical Solutions.